Spectrofluorometric Determination of Certain Antihyperlipidemic Agents in Bulk and Pharmaceutical Preparations

Abstract

A simple, rapid, and sensitive spectrofluorometric method was developed for the determination of three antihyperlipidemic drugs, namely, rosuvastatin calcium (RSV), ezetimibe (EZE), and pitavastatin calcium (PIT). The method is based on measuring the native fluorescence of the cited drugs at their optimum excitation and emission wavelengths. The fluorescence intensity was measured atλem 362 nm, 309 nm, and 373 nm upon excitation atλex 315 nm, 260 nm, and 245 nm for RSV, EZE, and PIT, respectively. The calibration graphs were linear over the concentration ranges 0.50–10.0, 0.25–4.0, and 0.10–3.00 μg mL−1for RSV, EZE, and PIT, respectively. Besides, a spectrofluorometric method for the simultaneous determination of RSV and EZE was developed. The fluorescence was measured atλem 309 nm for EZE and 432 nm for RSV upon excitation atλex 260 nm for both. The proposed methods were applied to the determination of the cited drugs either in bulk and pharmaceutical preparations.

Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review

“…Spectrophotometric methods with UV-Visible detection have been developed for ROS analysis alone and in simultaneous determination as presented in Table 1. [48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64] The matrices most employed in the studies were standard and pharmaceutical formulations, except for the spectrofluorimetric method developed by Braga et al [53] , which analyzed ROS in urine samples. The solvent most employed in spectrophotometric method was methanol (MeOH).…”

Spectrometric Determination of Rosuvastatin and Ezetimibe in Tablets by Multivariate Calibration Approach

“…Alzoman et al (2013) and Wani et al (2013) developed and applied a spectrophotometric method based on the charge transfer reaction between calcium rosuvastatin and π acceptors. El-Bagary also proposed a method for the determination of this drug (El-Bagary, Elkady, Kadry, 2012) in pharmaceutical preparations based on spectrophotometric determinations. Ezetimibe (EZE) (Figure 1a) is also an oral antilipidaemic agent and is chemically 1-(4fluorophenyl) -(3R)-[3-(4 fluorophenyl)-3S)-hydroxyphenyl]-4S-(4-hydroxyphenyl)-2azetidinone.…”

Densitometric Determination of Ezetimibe in the Presence of its Alkaline Degradation Product

“…Ezetimibe (EZE), a selective inhibitor of intestinal cholesterol and related phytosterol absorption, is designated as 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxy-phenyl)-2-azetidinone, It blocks the intestinal absorption of dietary and biliary cholesterol, without affecting the uptake of triglycerides or fat soluble vitamins, this reduce the overall delivery of cholesterol to the liver, thereby promoting the synthesis of LDL receptors and a subsequent reduction in serum LDL-C [1][2] . The literature is enriched with several techniques for determination of (EZE) in pharmaceutical dosage forms and/or biological fluids, including spectrophotometric methods [3][4][5][6][7][8][9][10][11] , chemometry 12 , spectrofluorometry 13 , electrochemical [14][15][16] , electrokinetic chromatographic method 17 , TLC [18][19][20] , LC [21][22][23] , HPLC 3,[24][25][26][27][28][29][30] , other related with degradation and elucidation of alkaline degradant of ezetimibe 31,32 .…”